Inventiva Showcases Positive Phase 2 Results for Lanifibranor

Inventiva's Promising Data on Lanifibranor and Empagliflozin

Inventiva, a clinical-stage biopharmaceutical company, is set to present the results from the final analysis of its Phase 2 study that evaluates the combination of lanifibranor with empagliflozin. This combination targets patients suffering from Metabolic Dysfunction-Associated Steatohepatitis (MASH) as well as Type 2 Diabetes (T2D). The findings will be shared during the late-breaker poster session at a prestigious event.

Study Outcomes and Efficacy Improvements

The results will be presented during a significant event, with expectations for attendees to gain insights about the study's successful outcomes. One of the most notable findings from this analysis is that the combination therapy significantly lowered Hemoglobin A1c (HbA1c) levels in patients compared to placebo. Specifically, 50% of patients saw their HbA1c levels drop below 6.5% after 24 weeks of treatment, demonstrating a strong efficacy signal for both treatment groups.

Numerical Achievements of the Study

In detail, the figures reflect that 58% of patients receiving lanifibranor alone experienced at least a 1% reduction in HbA1c, while 80% of those taking the combination therapy witnessed similar improvements. This is particularly striking when compared to the 0% noted in the placebo group, highlighting the therapy's effectiveness in managing diabetes related to MASH.

Comprehensive Health Benefits Observed

Not only did the treatment lead to better diabetes management, but it also showed improvements in liver function tests and various cardiometabolic health markers. Patients benefitted from enhancements in insulin sensitivity and reductions in inflammation markers. Moreover, the study noted no weight gain among patients on the combination therapy, contrasting with some mild increases seen in the lanifibranor-only group.

Clinical and Metabolic Insights

Imagery assessments indicated a significant reduction in hepatic steatosis, a key factor in MASH progression. Patients showcased a -49% reduction in fat content with lanifibranor alone and -41% when combined with empagliflozin. The results lend evidence to the potential for lanifibranor to address the underlying biology of MASH effectively.

Expert Opinions on Study Findings

Dr. Michael Cooreman, Chief Medical Officer of Inventiva, expressed enthusiasm about sharing these findings at the upcoming conference. He noted the importance of confirming lanifibranor's monotherapy benefits while supporting the treatment regime for patients through combination therapy. These insights are vital for healthcare practitioners and researchers focusing on this disease area.

Furthermore, Dr. Nezam Afdhal, a leading expert in gastroenterology, remarked on the significance of addressing insulin resistance through targeted treatments like lanifibranor and empagliflozin. He indicated that the results should alleviate common concerns around weight gain associated with certain diabetes therapies, empowering practitioners to choose effective combinations for managing T2D in MASH patients.

About Inventiva and its Future Prospects

Inventiva specializes in developing innovative therapies for metabolic diseases like MASH/NASH. Their lead candidate, lanifibranor, is currently undergoing pivotal Phase 3 trials. This concentrated pipeline showcases the company’s commitment to addressing significant unmet medical needs.

With a robust team of around 90 experts and proprietary access to a vast library of pharmacological compounds, Inventiva remains at the forefront of the biopharmaceutical industry. The team's strength lies in their vast experience with nuclear receptors and transcription factors.

Frequently Asked Questions

What is the primary focus of Inventiva?

Inventiva primarily focuses on developing oral small molecule therapies for metabolic diseases, particularly MASH/NASH.

What were the findings regarding weight management in the study?

The combination therapy of lanifibranor and empagliflozin did not result in weight gain, contrasting with the slight increase observed in those taking lanifibranor alone.

How effective was the therapy in managing diabetes?

50% of patients achieved HbA1c levels below 6.5% after 24 weeks, demonstrating significant efficacy in diabetes management.

Who are the key experts involved in this research?

Dr. Michael Cooreman and Dr. Nezam Afdhal are notable figures that have spoken positively about the study's outcomes and its implications for treating MASH and T2D.

What is the next step for Inventiva’s therapy development?

Inventiva is enhancing its clinical pipeline, focusing on lanifibranor through ongoing pivotal Phase 3 studies aiming for regulatory approval.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.